One of the world’s preëminent biomedical researchers is calling for a concerted effort by scientists to develop pills that would stay in the stomach or gut for weeks or months once swallowed, delivering one or more drugs continuously or over set intervals.
Such “super pills” would greatly simplify the treatment of diseases such as malaria. They could address a major concern in medicine, says MIT professor Robert Langer: the fact that many people don’t take all their drugs, especially when undergoing long-term treatment.
In certain workplaces, especially hospitals and restaurant kitchens, regular levels of bacteria are unsafe. In the past, UV lighting and chemicals have been used to disinfect fragile areas, but both of these options are unsafe for continuous use. Offering a new solution, Vital Vio is a disinfectant lighting which can reduce harmful micro-organisms by up to 99.9 percent, using harmless white light from specialized overhead light fixtures.
Imagine you’re a surgeon steeling yourself to operate on a child’s defective heart. In the future, doctors like you might be able to do a fail-safe trial run by snipping through a 3D image of the patient’s faulty cardiac anatomy while it floats in mid-air above a desktop.
That’s the ultimate goal for Mountain View, CA-based EchoPixel, a software startup that assembles data from 2D diagnostic scans and projects a three-dimensional map of an afflicted organ as a virtual reality image in open space.
Le "mal de dos", évoque sûrement une pathologie que vous connaissez bien. On estime que 85% de la population s'est plaint au moins une fois dans sa vie de douleurs liées à la colonne vertébrale. Souvent la douleur est suffisamment intense pour être invalidante et nuire aux performances professionnelles et à la qualité de vie.
Digital health firm Glooko has a new round of cash to expand its diabetes management product, but it’s not ready to say how much the product is actually helping diabetics.
The Palo Alto, CA-based company has raised a $16.5 million Series B round, led by Canaan Partners. With the cash, Glooko will add more ways to feed data into its product, which lets diabetics download personal and medical information from their health devices to a smart phone, and then share the data with doctors and insurers.
Health data analytics firms have come into vogue as health care providers struggle to reduce costs in the face of declining Medicare and Medicaid reimbursements. Many of these firms have proved to be attractive venture investment targets, and Salt Lake City-based Health Catalyst is a good example. The company has just pulled in a new $70 million round, bringing its investment total to somewhere around $170 million.
Dumb health care devices are no longer OK. With medical errors and redundancies costing us $750 billion a year, the push is on to digitize all forms of health information.
That’s probably one of the reason investors are betting another $2 million on Berkeley, California-based smart stethoscope company Eko.
For Medical Adhesive Revolution, a German-born biotech company, Houston has been good for business.
Last year, the company won the prestigious Rice University Business Plan Competition, becoming the first foreign company to do so. And this month, the biotech has officially moved its headquarters and its president, Alexander Schueller, to Houston where the company will join 21 other startups at the Texas Medical Center’s new accelerator, TMCx.
